Basilea Pharmaceutica
Update in progressBSLN.SW (Swiss)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. It markets Cresemba (isavuconazole) for invasive aspergillosis and mucormycosis and Zevtera (ceftobiprole) for pneumonia, Staphylococcus aureus bacteremia, ABSSSI, and community-acquired pneumonia. Its pipeline includes fosmanogepix (phase 3), ceftibuten-ledaborbactam etzadroxil (phase 3-ready for cUTI), BAL2062 (phase 2 for invasive aspergillosis), BAL2420 (preclinical). The company collaborates with Prokaryotics, Inc. and Phare Bio. Founded 2000, based in Allschwil, Switzerland.
Company score
- Sentiment
- 0.36
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.22
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
No news articles are available for this company yet.
Unable to load company news.
You're all caught up!